RESEARCH ARTICLE
Nobel Med 2008; 4(2): 19-25

THE EFFICACY OF CONVENTIONAL INTERFERON OR PEGYLATED INTERFERON IN COMBINATION WITH RIBAVIRIN IN TREATMENT OF CHRONIC HEPATITIS C AND A COMPARISON STUDY FOR ADVERS FFECTS RELATED TO TREATMENTS.

Habip Gedik, Ahmet Uludağ, Mehmet Yahyaoğlu, Cüneyt Müderrisoğlu, Muzaffer Fincancı
ABSTRACT
The efficacy and adverse events of standard interferon (alpha 2a or 2b) plus ribavirin versus pegylated interferon (alpha 2a or 2b) plus ribavirin in the treatment of Chronic Hepatitis C.

In this study the efficacy and adverse events of standard interferon alpha 2a (or 2b) plus ribavirin versus pegylated interferon alpha 2a (or 2b) plus ribavirin was evaluated in patients with chronic hepatitis C. A total of 98 naive patients with biopsy proven chronic hepatitis, elevated ALT levels, and positive HCV-RNA were enrolled. Fifty–six patients received standard interferon alpha 2a or 2b ( 3 MIU tiw) plus ribavirin for 52 weeks ( Group A) and 42 patients received pegylated interferon alpha-2b (1.5 µg/kg subcutaneously weekly ) or pegylated interferon alpha-2a (135 µg or 180 µg subcutaneously weekly) plus ribavirin for 52 weeks ( Group B). Baseline ALT levels were 79.05 ± 53.82 IU in group A; 106.5 ± 79.55 IU in group B, and fibrosis scores were 1.75 ± 1.16 in group A; 2 ± 1.31 in group B. In Group A genotype 1 was 91%; genotype 3a was 9% and in group B genotype 1 was 82%; genotype 3a was 10% and genotype 1+4 was 8% . End of treatment biochemical response was different between 89% in Group A and 78% in group B significantly (p: 0.038) , sustained virologic response was similar as 63% in group A and 73% in group B, and similar relapse rates of 17% in both groups
( p> 0.05). The percentages of adverse events were 92% and 97%, respectively ( p> 0.05).

The most common adverse event was asthenia. Standard interferon plus ribavirin was discontinued in 4 of 56; peginterferon plus ribavirin was discontinued in 5 of 42 (p> 0.05).

In conclusion, both combination therapeutic regimens reach more cure rates in the treatment of Chronic Hepatitis C compared with the others studies with less infected by HCV genotype-1 species. No significant difference on efficacy and adverse events between the two treatment schedules was observed in this study ( p> 0.05). Almost all of patients suffered from side-effects of drugs but they generally tolerated without interruption.
Keywords
Chronic hepatitis C Standard interferon alpha 2a or 2b Pegylated interferon alpha-2a or 2b Biochemical response Sustained virologic response Adverse effects

Article Details

Download Full Text in PDF Format Read Full Text Other Articles in This Issue

PHYSIOLOGICAL CHANGES IN OLD AGE

04-11

Selim Nalbant

REVIEW Nobel Med 2008; 4(2): 04-11

THERAPEUTIC PLASMA EXCHANGE IN HEMATOLOGICAL DISEASES

12-18

Gürhan Kadıköylü, Neslihan Soysal, İrfan Yavaşoğlu, Zahit Bolaman

REVIEW Nobel Med 2008; 4(2): 12-18

THE EFFICACY OF CONVENTIONAL INTERFERON OR PEGYLATED INTERFERON IN COMBINATION WITH RIBAVIRIN IN TREATMENT OF CHRONIC HEPATITIS C AND A COMPARISON STUDY FOR ADVERS FFECTS RELATED TO TREATMENTS.

19-25

Habip Gedik, Ahmet Uludağ, Mehmet Yahyaoğlu, Cüneyt Müderrisoğlu, Muzaffer Fincancı

RESEARCH ARTICLE Nobel Med 2008; 4(2): 19-25

CAN A NONSPECIFIC BACK PAIN BE ASSOCIATED WITH CAFFEINE CONSUMPTION AND DIETARY HABITS?

26-30

Demirhan Dıraçoğlu, Ayşe Karan, Aliye Aydoğan, Süreyya Şencan, Resa Aydın, Yusuf Orhan, Cihan Aksoy

RESEARCH ARTICLE Nobel Med 2008; 4(2): 26-30

IZOLE DALAK METASTAZI NEDENIYLE SPLENEKTOMI UYGULANAN OVER KARSINOMLU HASTA

31-32

Bülent Kaya, Deniz Güzey, Hasan Erdem

REPORT Nobel Med 2008; 4(2): 31-32

A RARE CASE OF TIBOLONE INDUCED TOXIC HEPATITIS

33-35

Erkan Cüre, Kasım Demir, Cem Koçkar, Abdülkadir Baştürk, Altuğ Şenol

REPORT Nobel Med 2008; 4(2): 33-35

ISTANBUL ÜNIVERSITESI REKTÖRLERINDEN ORD. PROF. TBP. TUĞGENERALTEVFIK SALIM SAĞLAM

36-40

Arın Namal, Şükrü Aras, Gül Kızılca Yürür

A PORTRAIT Nobel Med 2008; 4(2): 36-40

LIVER AND SYSTEMIC DISEASES

05-09

Sebati Özdemir

REVIEW Nobel Med 2013; 9(2): 5-9

AGING KIDNEY: SENESCENCE OR DISEASE?

10-14

Meltem Gürsu, Rümeyza Kazancıoğlu, Savaş Öztürk

REVIEW Nobel Med 2013; 9(2): 10-14

IMPORTANCE OF HOLOTRANSCOBALAMIN (HOLOTC) MEASUREMENTS IN EARLY DIAGNOSIS OF COBALAMIN DEFICIENCY, ESPECIALLY IN PATIENTS WITH BORDERLINE VITAMIN B12 CONCENTRATIONS

15-20

Faruk Sönmezışık, Esma Sürmen Gür, Burak Asıltaş

RESEARCH ARTICLE Nobel Med 2013; 9(2): 15-20

EVALUATION OF PHYSICAL GROWTH IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER

21-25

Celalettin Koşan, Oğuzhan Sepetçigil, Atilla Çayır, Avni Kaya, Behzat Özkan

RESEARCH ARTICLE Nobel Med 2013; 9(2): 21-25

COMPARISON OF RISK INDEXES USED IN DETERMINING THE POSTOPERATIVE RESPIRATORY INSUFFICIENCY RISK

26-31

Gülsüm Kavalcı, Cavidan Arar, Alkın Çolak, Nesrin Turan, Cemil Kavalcı

RESEARCH ARTICLE Nobel Med 2013; 9(2): 26-31

THE EVALUATION OF PRENATAL AND ENVIROMENTAL RISK FACTORS IN CHILDREN WITH ASTHMA, ALLERGIC RHINITIS AND BRONCHIAL ASTHMA ABSTRACT

32-37

Mehmet İbrahim Turan, Müferet Ergüven, Mehmet Özdemir

RESEARCH ARTICLE Nobel Med 2013; 9(2): 32-37

REOPERATIONS AND MORBIDITY IN THYROID SURGERY

38-42

Serkan Teksöz, Murat Özcan, Aytül Sargan, Yusuf Bukey, Recep Özgültekin, Ateş Özyeğin

RESEARCH ARTICLE Nobel Med 2013; 9(2): 38-42

EFFECTS OF RAMADAN FASTING ON BLOOD PRESSURE CONTROL, LIPID PROFILE, BRAIN NATRIURETIC PEPTIDE, RENAL FUNCTIONS AND ELECTROLYTE LEVELS IN HYPERTENSIVE PATIENTS TAKING COMBINATION THERAPY

43-46

İbrahim Faruk Aktürk, İsmail Bıyık, Cüneyt Koşaş, Ahmet Arif Yalçın, Mehmet Ertürk, Fatih Uzun

RESEARCH ARTICLE Nobel Med 2013; 9(2): 43-46

MANAGEMENT OF A LARGE OUTBREAK CAUSED BY NOROVIRUS AND CAMPYLOBACTER JEJUNI OCCURRED IN A RURAL AREA IN TURKEY

47-51

İbak Gönen

RESEARCH ARTICLE Nobel Med 2013; 9(2): 47-51

FREQUENT CD99 AND FLI-1 EXPRESSIONS IN DIFFUSE LARGE B-CELL LYMPHOMA AND THEIR ASSOCIATION WITH PROLIFERATIVE AND APOPTOTIC RATES

52-56

Ufuk Berber, İsmail Yılmaz, Tolga Tuncel, Zafer Küçükodacı Aptullah Haholu

RESEARCH ARTICLE Nobel Med 2013; 9(2): 52-56
  • Pubmed Style
    Habip Gedik, Ahmet Uludağ, Mehmet Yahyaoğlu, Cüneyt Müderrisoğlu, Muzaffer Fincancı. [KRONİK HEPATİT C TEDAVİSİNDE RİBAVİRİN İLE BİRLİKTE KULLANILMAKTA OLAN KLASİK İNTERFERON VEYA PEGİLE İNTERFERONUN ETKİNLİĞİ VE İLACA BAĞLI YAN ETKİLERİ AÇISINDAN KARŞILAŞTIRILMASI]. Nobel Med 2008; 4(2): 19-25, Turkish.
  • Web Style
    Habip Gedik, Ahmet Uludağ, Mehmet Yahyaoğlu, Cüneyt Müderrisoğlu, Muzaffer Fincancı. [KRONİK HEPATİT C TEDAVİSİNDE RİBAVİRİN İLE BİRLİKTE KULLANILMAKTA OLAN KLASİK İNTERFERON VEYA PEGİLE İNTERFERONUN ETKİNLİĞİ VE İLACA BAĞLI YAN ETKİLERİ AÇISINDAN KARŞILAŞTIRILMASI]. www.nobelmedicus.com/en/Article.aspx?m=1716 [Access: Mayıs 24, 2021], Turkish.
  • AMA (American Medical Association) Style
    Habip Gedik, Ahmet Uludağ, Mehmet Yahyaoğlu, Cüneyt Müderrisoğlu, Muzaffer Fincancı. [KRONİK HEPATİT C TEDAVİSİNDE RİBAVİRİN İLE BİRLİKTE KULLANILMAKTA OLAN KLASİK İNTERFERON VEYA PEGİLE İNTERFERONUN ETKİNLİĞİ VE İLACA BAĞLI YAN ETKİLERİ AÇISINDAN KARŞILAŞTIRILMASI]. Nobel Med 2008; 4(2): 19-25, Turkish.
  • Vancouver/ICMJE Style
    Habip Gedik, Ahmet Uludağ, Mehmet Yahyaoğlu, Cüneyt Müderrisoğlu, Muzaffer Fincancı. [KRONİK HEPATİT C TEDAVİSİNDE RİBAVİRİN İLE BİRLİKTE KULLANILMAKTA OLAN KLASİK İNTERFERON VEYA PEGİLE İNTERFERONUN ETKİNLİĞİ VE İLACA BAĞLI YAN ETKİLERİ AÇISINDAN KARŞILAŞTIRILMASI]. Nobel Med (2008); 4(2): 19-25, [cited Mayıs 24, 2021], Turkish.
  • Harvard Style
    Habip Gedik, Ahmet Uludağ, Mehmet Yahyaoğlu, Cüneyt Müderrisoğlu, Muzaffer Fincancı. (2008) [KRONİK HEPATİT C TEDAVİSİNDE RİBAVİRİN İLE BİRLİKTE KULLANILMAKTA OLAN KLASİK İNTERFERON VEYA PEGİLE İNTERFERONUN ETKİNLİĞİ VE İLACA BAĞLI YAN ETKİLERİ AÇISINDAN KARŞILAŞTIRILMASI]. Nobel Med, 4(2): 19-25, Turkish.